Interim report January-June 2015: Good growth and

Second quarter:

  · Sales amounted to SEK 184 (129) million, corresponding to an increase of 42
percent in SEK. Sales growth was 27 percent in local currency. The acquisition
of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 32 million
to sales. Adjusted for this, sales growth amounted to 5 percent in local
currency.
  · Operating income before depreciation and amortization (EBITDA) amounted to
SEK 62 (38) million, corresponding to a margin of 34 (29) percent. Fluctuations
in exchange rates had a positive effect of SEK 9 million on EBITDA.
  · Net income amounted to SEK 39 (23) million, which gave earnings per share of
SEK 1.77 (1.16).

First half year:

  · Sales amounted to SEK 347 (249) million, corresponding to an increase of 39
percent in SEK. Sales growth was 23 percent in local currency. The acquisition
of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 54 million
to sales. Adjusted for this, sales growth amounted to 4 percent in local
currency.
  · Operating income before depreciation and amortization (EBITDA) amounted to
SEK 116 (74) million, corresponding to a margin of 33 (30) percent. Fluctuations
in exchange rates had a positive effect of SEK 20 million on EBITDA.
  · Net income amounted to SEK 74 (46) million, which gave earnings per share of
SEK 3.38 (2.28).

Gothenburg, July 14, 2015
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel +46 31 721 80 01
Mikael Engblom, CFO, tel +46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on July
14, 2015 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife is an international medical device Group. Vitrolife Fertility product
area develops, produces and markets medical devices for assisted reproduction.
Work is also carried out to enable the use and handling of stem cells for
therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in
almost 110 markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United Kingdom, China,
Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX
Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Interim report January-June 2015: Good growth and strengthened income

Attachments
